ESTRF yields 20000000.00% · JNJ yields 2.13%● Live data
📍 ESTRF pulled ahead of the other in Year 1
Combined, ESTRF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ESTRF + JNJ for your $10,000?
Estre Ambiental, Inc., a waste management company, provides a range of waste-related and environmental services for municipal, commercial, and industrial customers in Brazil and Latin America. The company operates through four segments: Collection & Cleaning Services, O&G, Landfill, and Value Recovery. The Collection & Cleaning Services segment is involved in the industrial collection from large businesses, as well as local household collection, transportation, and temporary storage for environmental liability emergencies and industrial accidents, as well as in the preparation of waste for final disposal. The O&G segment engages in the provision of soil treatment and restoration services; and cleaning of storage tanks for the oil and gas industry. The Landfill segment provides treatment and waste disposal services, such as ground sealing, drainage and treatment of percolated liquid, rainwater catchment, and soil treatment with hydrocarbons. The Value Recovery segment is involved in the provision of energy recycling services; and dismantlement of electrical-electronic products. The company also engages in the collection and burning of landfill biogas, and electricity generation businesses. In addition, it offers environmental consulting, laboratory analysis, environmental consulting, recycling, and energy use services. Estre Ambiental, Inc. was founded in 1999 and is headquartered in São Paulo, Brazil.
Full ESTRF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.